{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:33:13Z","timestamp":1793406793730,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we have engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1\/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralize USA-WA1\/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of &gt;20; the neutralization geometric mean titers (GMTs) against the four viruses are 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s are 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1\/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages.<\/jats:p>","DOI":"10.1038\/s41467-022-30681-1","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T16:37:05Z","timestamp":1656002225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine"],"prefix":"10.1038","volume":"13","author":[{"given":"Chaitanya","family":"Kurhade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-7038","authenticated-orcid":false,"given":"Hongjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-6910","authenticated-orcid":false,"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-3943","authenticated-orcid":false,"given":"David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2273","authenticated-orcid":false,"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-4202","authenticated-orcid":false,"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-016X","authenticated-orcid":false,"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1616","authenticated-orcid":false,"given":"Pei\u2011Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"30681_CR1","doi-asserted-by":"publisher","unstructured":"Lyngse, F. P. et al. Transmission of SARS-CoV-2 omicron VOC subvariants BA.1 and BA.2: evidence from danish households. BioRxiv https:\/\/doi.org\/10.1101\/2022.1101.1128.22270044 (2022).","DOI":"10.1101\/2022.1101.1128.22270044"},{"key":"30681_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/2022.1102.1117.22271030","author":"N Wolter","year":"2022","unstructured":"Wolter, N., Jassat, W., von Gottberg, A. & Cohen, C., DATCOV-Gen author group. Clinical severity of omicron sub-lineage BA.2 compared to BA.1 in South Africa. MedRxiv https:\/\/doi.org\/10.1101\/2022.1102.1117.22271030 (2022).","journal-title":"MedRxiv"},{"key":"30681_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.02.015","author":"H Xia","year":"2022","unstructured":"Xia, H. et al. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host Microbe https:\/\/doi.org\/10.1016\/j.chom.2022.02.015 (2022).","journal-title":"Cell Host Microbe"},{"key":"30681_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28544-w","volume":"13","author":"J Zou","year":"2022","unstructured":"Zou, J. et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat. Commun. 13, 852 (2022).","journal-title":"Nat. Commun."},{"key":"30681_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04594-4","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature https:\/\/doi.org\/10.1038\/s41586-022-04594-4 (2022).","journal-title":"Nature"},{"key":"30681_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.06.22270533","author":"J Yu","year":"2022","unstructured":"Yu, J. et al. Comparable neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants. medRxiv https:\/\/doi.org\/10.1101\/2022.02.06.22270533 (2022).","journal-title":"medRxiv"},{"key":"30681_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/2021.1112.1131.474653","author":"TP Peacock","year":"2022","unstructured":"Peacock, T. P. et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. BioRxiv https:\/\/doi.org\/10.1101\/2021.1112.1131.474653 (2022).","journal-title":"BioRxiv"},{"key":"30681_CR8","doi-asserted-by":"publisher","unstructured":"Lyngse, F. P. et al. Nationwide study on SARS-CoV-2 transmission within households from lockdown to reopening, Denmark, 27 February 2020 to 1 August 2020. Euro Surveill https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.6.2001800 (2022).","DOI":"10.2807\/1560-7917.ES.2022.27.6.2001800"},{"key":"30681_CR9","doi-asserted-by":"publisher","unstructured":"Redd, A. D. et al. Minimal crossover between mutations associated with omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals. mBio https:\/\/doi.org\/10.1128\/mbio.03617-21 (2022).","DOI":"10.1128\/mbio.03617-21"},{"key":"30681_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"JM Ferdinands","year":"2022","unstructured":"Ferdinands, J. M. et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 255\u2013263 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"30681_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(22)00277-X","volume":"399","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. & Abu-Raddad, L. J. Waning effectiveness of COVID-19 vaccines. Lancet 399, 771\u2013773 (2022).","journal-title":"Lancet"},{"key":"30681_CR12","doi-asserted-by":"crossref","unstructured":"Tartof, S. Y. et al. BNT162b2 (Pfizer\u2013Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design. SSRN https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4011905 (2022).","DOI":"10.2139\/ssrn.4011905"},{"key":"30681_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2119451 (2022).","journal-title":"New Engl. J. Med."},{"key":"30681_CR14","unstructured":"Agency, U. H. S. COVID-19 vaccine surveillance report \u2013 Week 9, 3 March 2022. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1058464\/Vaccine-surveillance-report-week-1058469.pdf (2022)."},{"key":"30681_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"30681_CR16","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"New Engl. J. Med."},{"key":"30681_CR17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. New Engl. J. Med. 384, 1466\u20131468 (2021).","journal-title":"New Engl. J. Med."},{"key":"30681_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2113468","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med https:\/\/doi.org\/10.1056\/NEJMc2113468 (2021).","journal-title":"N. Engl. J. Med"},{"key":"30681_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848.e843 (2020).","journal-title":"Cell Host Microbe"},{"key":"30681_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"30681_CR21","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41596-021-00491-8","volume":"16","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat. Protoc. 16, 1761\u20131784 (2021).","journal-title":"Nat. Protoc."},{"key":"30681_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","volume":"592","author":"JA Plante","year":"2021","unstructured":"Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116\u2013121 (2021).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30681-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30681-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30681-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:46:49Z","timestamp":1669294009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30681-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30681"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30681-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.24.485633","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.X. and P.-Y.S. have filed a patent on the reverse genetic system of SARS-CoV-2. C.K., J.Z., H.X., X.X., and P.-Y.S. received compensation from Pfizer to perform the project. H.C., Q.Y., M.C., D.C., K.U.J., and K.A.S. are employees of Pfizer and may hold stock options. A.M. is an employee of BioNTech and may hold stock options. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3602"}}